Jinan Liangfu Jinghe Pharmaceutical Technology Co., Ltd.
MAILBOX | CHINESE | ENGLISH
Products
API & Intermediates
Cell Signaling Pathway Inhibitors
·Inhibitors of BTK Pathway
·Inhibitors of EGFR pathways
·Inhibitors of VEGFR pathways
·Inhibitors of PDGFR pathways
·Inhibitors of PI3K-Akt-mTOR pathways
·Inhibitors of IGF pathways
·Inhibitors of JAK-STAT pathway
·Inhibitors of MAPK/ERK pathway
·Inhibitors of apoptosis pathway
·Inhibitors of HIF-1 pathway
·Inhibitors of other pathways
Small Molecule Compounds
Impurity Reference Standards
Others
Contact Us
Address: 2766 Yingxiu Road, Jinan High-Tech Zone, China
Tel:
Sales: +86-531-88811783
Evaluation:+86-531-88806178
R&D: +86-531-88813691
Office: +86-531-88817621
Fax: +86-531-88817925
Zip Code: 250101
Email:
Trade Department:
sales@trio-pharmatech.com
G&D&E:
register@trio-pharmatech.com
yzxpj@trio-pharmatech.com
R&D center::
newdrugs@trio-pharmatech.com
Cell Signaling Pathway Inhibitors Now Position:Home > Products > Cell Signaling Pathway Inhibitors < Inhibitors of BTK Pathway
PCI-32765; Ibrutinib(CAS:936563-96-1)

Product No.

TP1130A 

Name

PCI-32765; Ibrutinib

Synonyms

PCI-32765; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one

CAS Number

936563-96-1

Structure

Brief Description

Ibrutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK. It has given good results in two phase II clinical trials, and currently under evaluation in several phase III clinical trials.

Purity

>99%

Package

5mg10mg20mg50mg

 





Close
QQ1: 1762738062
QQ2: 1919147143
MSN: sales-trio
SKYPE: janisa.yan